Marketing pieces

Quote












The name of the game is equity. How much do you have? Leadership depends on you to grow their pockets. The better you do, the BETTER they do. It’s not just here at Supernus, trust me. Let’s just say that 500 shares is pretty low ball.
 












anonymous said:
What a loser. Couldn’t hack it here but you still wanted to drop by and see what’s going on. Do us all a favor and stay off cafepharma. Supernus is doing better than anyone in Migraine or Epilepsy and soon will be top on Psychiatic as well. Go away troll and leave the successful sales people alone.
Click to expand...

False but ok. We doing ok for what we have. Vimpat still crushing epilepsy and CGRP’s as a whole soon to beat us in migraine and we never getting patients doing fine on iR topiramate. With that being said there’s still business to get for both products.
 






Just curious if anyone else here feels torn morally regarding our medications and the costs for them? I mean our own insurance here won’t cover these meds and the molecules are well over 20 years old. I’m someone will hop on here and call me an idiot but I can’t be the only one who feels this way. We literally sell against generic affordable medications every call, not other molecules. I think I’ll just stay in bed today.
 






I’ll call you an idiot. Better tolerable versions of a molecule can be life changing. The cost is in the r&d and we have to pay for that to get the drug to market. The name of the game is make money. How we do that is by improving lives. My beef is that since I started here I’ve been told that I’d have a new drug to sell in less than 2 years. Every. Year. I’ve. Worked. Here.
 
























It’s not happening in 2020. Rumblings from Rockville are planning for a summer 2022 game plan. The goal is to keep it low key till they have a better idea when Oxt or Trok go generic. The other meds in the pipe are 6-10 years away and they don’t want to get stranded without any meds in 8 years.
 






anonymous said:
It’s not happening in 2020. Rumblings from Rockville are planning for a summer 2022 game plan. The goal is to keep it low key till they have a better idea when Oxt or Trok go generic. The other meds in the pipe are 6-10 years away and they don’t want to get stranded without any meds in 8 years.
Click to expand...
So you’re saying there’s a chance....
 






anonymous said:
It’s not happening in 2020. Rumblings from Rockville are planning for a summer 2022 game plan. The goal is to keep it low key till they have a better idea when Oxt or Trok go generic. The other meds in the pipe are 6-10 years away and they don’t want to get stranded without any meds in 8 years.
Click to expand...


You must have forgot the two drugs that already have ph3 data
 






God I hope not. I actually like Supernus and the people I work for but 3 more years of this wow. Anybody have any real info, other than “rumblings”. Probably just an old Shire rep about to be laid off from Takeda. Cause right now I’m calling bs on that 2022
 






anonymous said:
It’s not happening in 2020. Rumblings from Rockville are planning for a summer 2022 game plan. The goal is to keep it low key till they have a better idea when Oxt or Trok go generic. The other meds in the pipe are 6-10 years away and they don’t want to get stranded without any meds in 8 years.
Click to expand...

“Get stranded” the skipper and gilligan called and we are almost stranded as is.
 






anonymous said:
It’s not happening in 2020. Rumblings from Rockville are planning for a summer 2022 game plan. The goal is to keep it low key till they have a better idea when Oxt or Trok go generic. The other meds in the pipe are 6-10 years away and they don’t want to get stranded without any meds in 8 years.
Click to expand...

Yeah this is bull.

Couple of give aways but the biggest is we already know(and it’s public info) when our current products lose patent protection. And then the fact that no one calls them “Oxt or Trok” lol. If you do, bless you child.
 






























Top Bottom
Back
Quote